With over 20 years experience in senior HEOR & RWE leadership roles, Canter leads our group to provide clients with the path to access & improved patient outcomes through strategic planning, proven evidence generation methodologies, & effective value communications. His team is inspired to answer client’s most challenging clinical & commercial questions, as well as meet the highest standards of project delivery & compliance.
Canter also oversees HCG’s HEOR & RWE strategic partnerships with the industry’s leading health services & data providers to drive innovation & support our clients’ needs in a dynamic global market.

Kathy is a health services researcher with more than 20 years of experience managing real-world datasets and utilizing real-world data for clinical & economic research. She has extensive experience leading data-driven projects for pharmaceutical & medical device companies using many research designs across many therapeutic areas. Her research has been presented at national & international scientific conferences & published in peer-reviewed journals. Kathy also has experience with hospital quality initiatives, previously serving as analytics lead for a pay-for-performance demonstration pilot project with the Centers for Medicare & Medicaid Services.

Dr. Phillip Hivale has 10 + years in managed markets, value-based contracting, FDA/BLA policies, access and reimbursement, brand strategy, and health and economic outcomes. He has collaborated alongside numerous healthcare stakeholders and formulary decision-makers to gain consumer insights across payers, IDNs, and health systems. He has also worked directly with a number of pharmaceutical manufacturers to optimize their market access strategy and overall value messaging. Within a dynamically changing market, Phillip’s critical understanding of clinical and budget impact within the healthcare system has allowed him to provide an extremely unique expertise for each one of his clients.

Dr. Ramiro Gilardino brings 12+ years of experience in health economics, outcomes research, and global health policy in pharmaceutical, medical devices companies, and not-for-profit organizations both at the regional and global reach.
He developed customer-centered value propositions, registry studies, claims analysis, among several market access and health economics tactics supporting access to medical technologies. He also was engaged in health policy matters, including health technology assessment policies, patient engagement, and value assessment, where he worked among decision-makers in Europe and emerging markets in LATAM and CEMEA.